Combinations in multimodality treatments and clinical outcomes during cancer (Review) Retraction in /10.3892/ol.2020.12083

Zhang,Xiao‑Ying; Zhang,Pei‑Ying

doi:10.3892/ol.2016.5242

Combinations in multimodality treatments and clinical outcomes during cancer (Review)

Retraction in: /10.3892/ol.2020.12083

Authors:
- Xiao‑Ying Zhang
- Pei‑Ying Zhang
View Affiliations

Affiliations: Nanjing University of Chinese Medicine, Information Institute, Nanjing, Jiangsu 221009, P.R. China, Department of Cardiology, Xuzhou Central Hospital, The Affiliated Xuzhou Hospital of Medical College of Southeast University, Xuzhou, Jiangsu 221009, P.R. China
Published online on: October 11, 2016 https://doi.org/10.3892/ol.2016.5242
Pages: 4301-4304
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Combination approach could be easily considered as the future of therapeutics in all pathological states including cancer. Scientists are trying different combinations in order to determine synergism among different therapeutics which ultimately helps in the improved and more efficient management of the affected patients. Combination of multi-chemotherapeutic agents, or multi‑drug therapy, may be the most commonly used strategy for cancer treatment. Monotherapy causes drug resistance and loses its response in patients after several cycles of treatment. While combining different anticancer drugs together for cancer treatment, as in the case of the cocktail therapy for HIV, not only overcomes the drug resistance but also leads to a synergistic effect, therefore showing prolonged survival for patients. The present review article is focused on different combinations in use for better efficiency of therapeutics against cancer. We searched the electronic database PubMed for pre‑clinical as well as clinical controlled trials reporting diagnostic as well as therapeutic advances of various combinations in cancer. It was observed clearly that combination approach is better in various aspects including increase in efficacy, specificity and decline in the unwanted side effects.

View Figures

View References

1	Prieto PA, Reuben A, Cooper ZA and Wargo JA: Targeted Therapies Combined With Immune Checkpoint Therapy. Cancer J. 22:138–146. 2016. View Article : Google Scholar : PubMed/NCBI
2	Zhang Z, Guo Y and Feng SS: Nanoimmunotherapy: Application of nanotechnology for sustained and targeted delivery of antigens to dendritic cells. Nanomedicine (Lond). 7:1–4. 2012. View Article : Google Scholar : PubMed/NCBI
3	Rosenberg SA, Yang JC and Restifo NP: Cancer immunotherapy: Moving beyond current vaccines. Nat Med. 10:909–915. 2004. View Article : Google Scholar : PubMed/NCBI
4	Melero I, Grimaldi AM, Perez-Gracia JL and Ascierto PA: Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res. 19:997–1008. 2013. View Article : Google Scholar : PubMed/NCBI
5	Mellman I, Coukos G and Dranoff G: Cancer immunotherapy comes of age. Nature. 480:480–489. 2011. View Article : Google Scholar : PubMed/NCBI
6	Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A, Betts MR, Freeman GJ, Vignali DA and Wherry EJ: Coregulation of CD8⁺ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 10:29–37. 2009. View Article : Google Scholar : PubMed/NCBI
7	Yu P, Steel JC, Zhang M, Morris JC and Waldmann TA: Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model. Clin Cancer Res. 16:6019–6028. 2010. View Article : Google Scholar : PubMed/NCBI
8	Ramos-Suzarte M, Lorenzo-Luaces P, Lazo NG, et al: Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy. Cancer Biol Ther. 13:600–605. 2012. View Article : Google Scholar : PubMed/NCBI
9	Dong JM, Zhao SG, Huang GY and Liu Q: NADPH oxidase-mediated generation of reactive oxygen species is critically required for survival of undifferentiated human promyelocytic leukemia cell line HL-60. Free Radic Res. 38:629–637. 2004. View Article : Google Scholar : PubMed/NCBI
10	Oleson JR: Eugene Robertson Special Lecture. Hyperthermia from the clinic to the laboratory: A hypothesis. Int J Hyperthermia. 11:315–322. 1995. View Article : Google Scholar : PubMed/NCBI
11	Vujaskovic Z and Song CW: Physiological mechanisms underlying heat-induced radiosensitization. Int J Hyperthermia. 20:163–174. 2004. View Article : Google Scholar : PubMed/NCBI
12	Sanson C, Diou O, Thévenot J, Ibarboure E, Soum A, Brûlet A, Miraux S, Thiaudière E, Tan S, Brisson A, et al: Doxorubicin loaded magnetic polymersomes: Theranostic nanocarriers for MR imaging and magneto-chemotherapy. ACS Nano. 5:1122–1140. 2011. View Article : Google Scholar : PubMed/NCBI
13	Kouloulias V, Plataniotis G, Kouvaris J, Dardoufas C, Gennatas C, Uzunoglu N, Papavasiliou C and Vlahos L: Chemoradiotherapy combined with intracavitary hyperthermia for anal cancer: Feasibility and long-term results from a phase II randomized trial. Am J Clin Oncol. 28:91–99. 2005. View Article : Google Scholar : PubMed/NCBI
14	Westermann AM, Jones EL, Schem BC, et al: First results of triple-modality treatment combining radiotherapy, chemotherapy, and hyperthermia for the treatment of patients with stage IIB, III, and IVA cervical carcinoma. Cancer. 104:763–770. 2005. View Article : Google Scholar : PubMed/NCBI
15	Westermann A, Mella O, Van Der Zee J, Jones ELE, Van Der Steen-Banasik E, Koper P, Uitterhoeve AL, De Wit R, Van Der Velden J, Burger C, et al: Long-term survival data of triple modality treatment of stage IIB-III-IVA cervical cancer with the combination of radiotherapy, chemotherapy and hyperthermia - an update. Int J Hyperthermia. 28:549–553. 2012. View Article : Google Scholar : PubMed/NCBI
16	Vujaskovic Z, Kim DW, Jones E, Lan L, McCall L, Dewhirst MW, Craciunescu O, Stauffer P, Liotcheva V, Betof A and Blackwell K: A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer. Int J Hyperthermia. 26:514–521. 2010. View Article : Google Scholar : PubMed/NCBI
17	Tschoep-Lechner KE, Milani V, Berger F, Dieterle N, Abdel-Rahman S, Salat C and Issels RD: Gemcitabine and cisplatin combined with regional hyperthermia as second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer. Int J Hyperthermia. 29:8–16. 2013. View Article : Google Scholar : PubMed/NCBI
18	Wessalowski R, Kruck H, Pape H, Kahn T, Willers R and Göbel U: Hyperthermia for the treatment of patients with malignant germ cell tumors: A phase I/II study in ten children and adolescents with recurrent or refractory tumors. Cancer. 82:793–800. 1998. View Article : Google Scholar : PubMed/NCBI
19	Issels RD: Hyperthermia adds to chemotherapy. Eur J Cancer. 44:2546–2554. 2008. View Article : Google Scholar : PubMed/NCBI
20	Lindquist S and Craig EA: The heat-shock proteins. Annu Rev Genet. 22:631–677. 1988. View Article : Google Scholar : PubMed/NCBI
21	Kumar CS and Mohammad F: Magnetic nanomaterials for hyperthermia-based therapy and controlled drug delivery. Adv Drug Deliv Rev. 63:789–808. 2011. View Article : Google Scholar : PubMed/NCBI
22	Boisselier E and Astruc D: Gold nanoparticles in nanomedicine: Preparations, imaging, diagnostics, therapies and toxicity. Chem Soc Rev. 38:1759–1782. 2009. View Article : Google Scholar : PubMed/NCBI
23	Day ES, Morton JG and West JL: Nanoparticles for thermal cancer therapy. J Biomech Eng. 131:0740012009. View Article : Google Scholar : PubMed/NCBI
24	Kerbel R and Folkman J: Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2:727–739. 2002. View Article : Google Scholar : PubMed/NCBI
25	Folkman J: Angiogenesis: An organizing principle for drug discovery? Nat Rev Drug Discov. 6:273–286. 2007. View Article : Google Scholar : PubMed/NCBI
26	Folkman J: Angiogenesis. Annu Rev Med. 57:1–18. 2006. View Article : Google Scholar : PubMed/NCBI
27	Kamrava M, Bernstein MB, Camphausen K and Hodge JW: Combining radiation, immunotherapy, and antiangiogenesis agents in the management of cancer: The Three Musketeers or just another quixotic combination? Mol Biosyst. 5:1262–1270. 2009. View Article : Google Scholar : PubMed/NCBI
28	Kandalaft LE, Powell DJ Jr, Chiang CL, Tanyi J, Kim S, Bosch M, Montone K, Mick R, Levine BL, Torigian DA, et al: Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. OncoImmunology. 2:e226642013. View Article : Google Scholar : PubMed/NCBI
29	Fabi A, Russillo M, Ferretti G, Metro G, Nisticò C, Papaldo P, De Vita F, D'Auria G, Vidiri A, Giannarelli D and Cognetti F: Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: Efficacy in combination with hormonal therapy. BMC Cancer. 12:4822012. View Article : Google Scholar : PubMed/NCBI
30	Dolmans DEJGJ, Fukumura D and Jain RK: Photodynamic therapy for cancer. Nat Rev Cancer. 3:380–387. 2003. View Article : Google Scholar : PubMed/NCBI
31	Baldea I and Filip AG: Photodynamic therapy in melanoma - an update. J Physiol Pharmacol. 63:109–118. 2012.PubMed/NCBI
32	Zuluaga MF and Lange N: Combination of photodynamic therapy with anti-cancer agents. Curr Med Chem. 15:1655–1673. 2008. View Article : Google Scholar : PubMed/NCBI
33	Brown SB, Brown EA and Walker I: The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol. 5:497–508. 2004. View Article : Google Scholar : PubMed/NCBI
34	Agostinis P, Berg K, Cengel KA, Foster TH, Girotti AW, Gollnick SO, Hahn SM, Hamblin MR, Juzeniene A, Kessel D, et al: Photodynamic therapy of cancer: An update. CA Cancer J Clin. 61:250–281. 2011. View Article : Google Scholar : PubMed/NCBI
35	Friedberg JS, Mick R, Stevenson J, Metz J, Zhu T, Buyske J, Sterman DH, Pass HI, Glatstein E and Hahn SM: A phase I study of Foscan-mediated photodynamic therapy and surgery in patients with mesothelioma. Ann Thorac Surg. 75:952–959. 2003. View Article : Google Scholar : PubMed/NCBI
36	Thomas CE, Ehrhardt A and Kay MA: Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet. 4:346–358. 2003. View Article : Google Scholar : PubMed/NCBI
37	McCormick F: Cancer gene therapy: Fringe or cutting edge? Nat Rev Cancer. 1:130–141. 2001. View Article : Google Scholar : PubMed/NCBI
38	DeVincenzo JP: The promise, pitfalls and progress of RNA-interference-based antiviral therapy for respiratory viruses. Antivir Ther 17 (1 Pt B). 213–225. 2012. View Article : Google Scholar
39	Izquierdo M: Short interfering RNAs as a tool for cancer gene therapy. Cancer Gene Ther. 12:217–227. 2005. View Article : Google Scholar : PubMed/NCBI
40	Ginn SL, Alexander IE, Edelstein ML, Abedi MR and Wixon J: Gene therapy clinical trials worldwide to 2012 - an update. J Gene Med. 15:65–77. 2013. View Article : Google Scholar : PubMed/NCBI
41	Davidson BL and McCray PB Jr: Current prospects for RNA interference-based therapies. Nat Rev Genet. 12:329–340. 2011. View Article : Google Scholar : PubMed/NCBI